Hereditary Angioedema (HAE)
Conditions
Interventions
None listed
Sponsors
Takeda Pharmaceutical Company Limited
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Patients who were diagnosed as HAE (Type 1, Type 2, HAE-nC1-INH ) (40 subjects of type 1 or 2, and at most 10 subjects of HAE-nC1-INH) 2.Patients who have experienced two or more attacks of HAE in the past half year from the time of consent 3.Patients aged 12 years or older when providing informed consent 4.Patients judged by the principal investigator or subinvestigator to understand and comply with the study, and to be able to operate the devices 5.Patients who can sign and date the informed consent form by themselves or, if applicable, legally acceptable representatives of the patients prior to the study procedure
Exclusion criteria
Exclusion criteria: 1.Patients who have severe complications (e.g., uncontrolled hypertension, diabetes mellitus, heart failure, etc.) and judged to have difficulty performing normal daily physical activities 2.Patients who have difficulty wearing wearable devices used in this study on a daily basis 3.Patients who are considered ineligible for this study for other reasons by the principal investigator or subinvestigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| -Differences in data from various biological data from a wearable device within 48 hours prior to HAE attack and for 48 hours without HAE attack -Correlation coefficients between HAE attack frequency and various data from a wearable device | — |
Secondary
| Measure | Time frame |
|---|---|
| -To examine the occurrence of attacks and associated behaviors -To develop prediction models and investigate the factors that trigger attacks | — |
Countries
Japan
Contacts
Public ContactSuzuki Yuta
Mebix, Inc. Division of research promotion
Outcome results
None listed